SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J 2004; 24: 33940.
  • 2
    Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, 2001. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (last accessed 17 June 2009).
  • 3
    Stavros FL, Kramer WG, Ogilvie BW, Parkinson A. The victim potential of sitaxentan: metabolism by human CYP enzymes. European Respiratory Society 2008; abstract 2667.
  • 4
    Pfizer. Revatio (sildenafil citrate) Prescribing Information. 2008.
  • 5
    Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 10712.
  • 6
    Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64: 4350.